Supplementary material

Supplementary Table 1: Primers for the amplification of the *HGF* promoter, DATE nested PCR primers and sequencing primers

Amplification Primers			
2.0kpHGF For	5′-	GGAACATGTGATTCTTCTCCTCGTGGGGT	-3′
3.4kpHGF Rev	5′-	TGTCAGCCTCTGTCTGGTGTCCCC	-3′
3.3kpHGF For	5′-	TCAGGGTCACGGTCAGGCTATGC	-3′
4.7kpHGF Rev	5′-	GGCACAGGCAGGGGACCAATTCGC	-3′
3.2kpHGF For	5′-	CAGAGAGAGCTGATTCTGAGGTCTTC	-3′
4.3kpHGF Rev	5′-	CTGCCAAACTCACGAAATACCACAC	-3′
HGF_DATEoutFor	5′-	GTCCAAAGCAGCCAAGTTCAGCCAG	-3′
5.5kpHGF Rev	5′-	GGGACAGGCTATGGACAATGACTGTTTCTTGG	-3′
DATE nested Primers		As described in (19)	
HGF_DATEoutFor	5′-	GGGACAGGCTATGGACAATGACTGTTTCTTGG	-3′
HGF_DATEoutRev	5′-	GGGTGTGGTATTGTGGGGCCAAAATAAG	-3′
HGF_DATEinFor	5′-	CGTGAGTTTGGCAGTTTGTG	-3′
HGF_DATEinRev	5′-	ATGGGCTCAGAGCAGGCAGC	-3′
Sequencing Primers			
2.7kpHGFSeq1	5'-	ACCCGAGAGCCTTTAGAAC	-3'
2.7kpHGFSeq2	5'-	TCATTTTTCTGAGCCCCTAC	-3'
2.7kpHGFSeq3	5'-	AGTTACCAGAGCATCCACC	-3'
pHGF-5-Seq	5'-	GGTGAAAGTCAGTCCTAACCAG	-3'
pHGF-Seq3	5'-	GTGCCTTGATTTAGCCATTG	-3'
pHGFSeqRev2	5'-	TGGCTAAATCAAGGCACAG	-3'
pHGFSeqRev3	5'-	AACAGTCATTGTCCATAGCC	-3'
pHGFSeqRev4	5'-	CCAAAGTGTAAGTGGAAAGATGAGG	-3'
pHGFSeqRev5	5'-	TTGTCAGCCTCTGTCTGGTGTCC	-3'
pHGFSeqRev6	5'-	CCATTCCAAAGAAGGTCC	-3'

Supplementary Table 2: Cytogenetic status of the patient samples

Patient	Age at sampling	Gender	Hyperdiploidy		Other Cytogenetics	Treatment status	% PC in BM
MM 1	55	M		Three copies *HGF* Three copies *CEP7*	N.A.	Newly Diagnosed / Untreated	17
MM 2	74	M		Two copies *HGF*	Normal *IGH*, del17 Positive del13	Newly Diagnosed / Untreated	66
MM 3	65	M		Two copies *HGF*	Normal *IGH*, del13 and del17	Newly Diagnosed / Untreated	60
MM 4	81	M		One copy *HGF*	t(14;16) Normal del13 and del17	Newly Diagnosed / Untreated	95
MM 5	72	M		Two copies *HGF*	Normal *IGH*, del13, del17, *IGK*, *IGL*	Newly Diagnosed / Untreated	60
MM 6	77	M		Two copies *HGF*	t(11;14) Normal del13 Normal del17, 1p & gain 1q	Newly Diagnosed / Untreated	20
MM 7	65	F		One copy *HGF*	t(11,14) Positive del13 Normal del17	Newly Diagnosed / Untreated MGUS diagnosed in 2004	45
MM 8	72	M		Three copies *HGF*	Normal *IGH* & del17 Positive del13 Normal 1p & gain 1q	Diagnosed in August 2006 / Treated	>95
MM 9	81	M		Two copies *HGF*	Normal *IGH*, del13, del17, 1p & 1q	N.A.	N.A.
MM 10	62	M		Two copies *HGF*	t(11;14) Positive del13 Normal del17, 1p & 1q	Newly Diagnosed / Untreated	40
MM 11	73	M		Three copies *HGF*	Normal *IGH*, del17, 1p & 1q Positive del13 *IGK* split	Newly Diagnosed / Untreated	>30
MM 12	67	M	N.A.	N.A.	t(4;14), t(2;8) Positive del13 Normal del17	Newly Diagnosed / Untreated	5-10
MM 13	71	M	N.A.	Three copies *HGF*	Normal *IGH*, del17, 1p & 1q Positive del13	Newly Diagnosed / Untreated	28

Supplementary Table 2: Continued

Patient	Age at sampling	Gender	Hyperdiploidy		Other Cytogenetics	Treatment status	% PC in BM
MM 14	81	F		Two copies *HGF*	Unknown *IGH* split Positive del13 Normal del17, 1p & 1q	Newly Diagnosed / Untreated	60
MM 15	56	M		Two copies *HGF*	Normal *IGH*, del13, del17, 1p & 1q	Newly Diagnosed / Untreated	31
MM 16	63	M		One copy *HGF*	Normal *IGH*, del13 and del17	Newly Diagnosed / Untreated	8
MM 17	57	M		Three copies *HGF*	Normal *IGH*, del13, *MYC*, 1p & gain 1q	Newly Diagnosed / Untreated	5
MM 18	80	F		Two copies *HGF*	Normal *IGH*, del 17, 1p, 1q, *CEP15* Positive del13 Triploid 9	Diagnosed in 2005 / Untreated	13
MM 19	67	F		Two copies *HGF*	t(11;14) Positiv del13 Normal del17, 1p & gain 1q	Newly Diagnosed / Untreated	10
MM 20	80	F	N.A.	N.A.	Normal *IGH* del17, *MYC*, 1p, 1q, *CEP9*, *CEP19*, positiv del13	Newly Diagnosed / Untreated	44
MM 21	56	M	N.A.	N.A.	t(4;14) Positiv del13 and del17, normal 1p gain 1q	Newly Diagnosed / Untreated	7
MM 22	53	M	N.A.	N.A.	Unknown *IGH* split Normal del13 and del17	N.A.	N.A.
MM 23	60	M		Two copies *HGF*	Unknown *IGH* split Positive del13 and del17 Normal 1q & 1q	N.A.	N.A.
MM 24	68	M	N.A.	N.A.	t(11;14) Normal del13 and del17, deletion 1p & gain 1q	N.A.	N.A.
MM 25	72	M		Three copies *HGF* Three copies *CEP7*	t(11;14) Normal del13 del17, 1p & 1q	N.A.	N.A.
MM 26	36	M		Two copies *HGF*	t(4;14) Positive del13 Normal del17, 1p & 1q	Newly Diagnosed / Untreated	N.A.

Supplementary Table 2: Continued

Patient	Age at sampling	Gender	Hyperdiploidy		Other Cytogenetics	Treatment status	% PC in BM
MM 27	53	F		Two copies *HGF*	t(11;14) Positive del13 del17, del 1p, Normal 1q	Cells isolated after first CyDex treatment / Serum withdrawn after ASCT	N.A.
MM 28	59	M		Three copies *HGF*	Unknown *IGH* split Normal del13 Positive del17	N.A.	N.A.
MM 29	66	F	N.A.	N.A.	t(11;14) Normal del13 del17,1p & 1q	N.A.	N.A.
MM 30	58	M		Three copies *HGF*	t(11;14) Normal del13 del17,1p & 1q	N.A.	N.A.

M Male
F Female
BM Bone Marrow
N.A. Not Analyzed
PC Plasma cells
CyDex Cyclophosphamide and Dexamethasone treatment (proceeds ASCT)
ASCT Autologous Stem Cell Therapy